- Home
- / Precipio
Precipio
Stock Price
$6.3
2024-10-29
Market Capitalization
$9.3 M
2024-10-29
Revenue
$24 M
FY, 2025
Precipio Summary
Company Summary
- Overview
- Precipio (formerly Transgenomic) is a company operating as a cancer diagnostics reference laboratory providing products and services to the oncology market. It develops a proprietary hematologic malignancy mutation profile screening panel and other products
- Type
- Public
- Status
- Active
- Founded
- 1997
- HQ
- Omaha, NE, US | view all locations
- Website
- http://www.precipiodx.com/
- Cybersecurity rating
Table of Contents
Key People
Mark Rimer, Board Member
Ron A. Andrews (Ronnie), Director
Richard Sandberg, Chairman of the Board
LocationsView all
4 locations detected
Omaha, NE HQ
United States
12325 Emmet St
New Haven, CT
United States
5 Science Park
Omaha, NE
United States
8813 F St
Glasgow, Scotland
United Kingdom
40 Watt Rd
Precipio Financials
Summary Financials
- Revenue (Q1, 2026)
- $6.7M
- Gross profit (Q1, 2026)
- $2.7M
- Net income (Q1, 2026)
- ($1.4M)
- Cash (Q1, 2026)
- $2.6M
- Enterprise value
- $10.0M